Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 1
1994 6
1995 15
1996 44
1997 84
1998 165
1999 257
2000 273
2001 344
2002 384
2003 472
2004 488
2005 529
2006 601
2007 543
2008 583
2009 471
2010 508
2011 524
2012 523
2013 547
2014 496
2015 442
2016 440
2017 440
2018 405
2019 412
2020 456
2021 499
2022 488
2023 404
2024 479
2025 516
2026 382

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,912 results

Results by year

Filters applied: . Clear all
Page 1
[Olanzapine].
Nagai N, Watanabe K. Nagai N, et al. Nihon Rinsho. 2013 Apr;71(4):666-72. Nihon Rinsho. 2013. PMID: 23678597 Review. Japanese.
Olanzapine is one of the SGAs (second-generation antipsychotics) which have been used for the treatment of patients with schizophrenia and bipolar disorder in Japan. ...Therefore, olanzapine is known as MARTA(multi-acting receptor targeted antipsychotics). Numerous …
Olanzapine is one of the SGAs (second-generation antipsychotics) which have been used for the treatment of patients with schizophreni …
Olanzapine/Samidorphan: First Approval.
Paik J. Paik J. Drugs. 2021 Aug;81(12):1431-1436. doi: 10.1007/s40265-021-01568-0. Drugs. 2021. PMID: 34304374 Review.
Samidorphan, which was developed by Alkermes, is an opioid receptor antagonist that has been co-formulated with olanzapine into a single-dose oral tablet to mitigate the risk of weight gain while providing the therapeutic effect of olanzapine. Olanzapine/sami …
Samidorphan, which was developed by Alkermes, is an opioid receptor antagonist that has been co-formulated with olanzapine into a sin …
[Olanzapine].
Wittköpper K, El-Armouche A, Eschenhagen T. Wittköpper K, et al. Dtsch Med Wochenschr. 2008 Sep;133(39):1958-62. doi: 10.1055/s-0028-1085603. Epub 2008 Sep 16. Dtsch Med Wochenschr. 2008. PMID: 18798132 Review. German. No abstract available.
Olanzapine for schizophrenia.
Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Duggan L, et al. Cochrane Database Syst Rev. 2000;(2):CD001359. doi: 10.1002/14651858.CD001359. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2003;(1):CD001359. doi: 10.1002/14651858.CD001359. PMID: 10796640 Updated.
MAIN RESULTS: Twenty trials are included. Attrition from olanzapine versus placebo studies was so great (olanzapine - 61%, placebo - 73% by six weeks, RR 0.85 CI 0. 7-0.98, NNT 8 CI 5-40) that interpretation of results is problematic. ...Dizziness and dry mouth were …
MAIN RESULTS: Twenty trials are included. Attrition from olanzapine versus placebo studies was so great (olanzapine - 61%, pla …
Olanzapine for schizophrenia.
Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Duggan L, et al. Cochrane Database Syst Rev. 2003;(1):CD001359. doi: 10.1002/14651858.CD001359. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2005 Apr 18;(2):CD001359. doi: 10.1002/14651858.CD001359.pub2. PMID: 12535408 Updated.
MAIN RESULTS: Twenty one trials are included. Attrition from olanzapine versus placebo studies was so great (olanzapine - 61%, placebo - 73% by six weeks, RR 0.85 CI 0.7-0.98, NNT 8 CI 5-40) that interpretation of results is problematic. ...Although dizziness and dr …
MAIN RESULTS: Twenty one trials are included. Attrition from olanzapine versus placebo studies was so great (olanzapine - 61%, …
Olanzapine for schizophrenia.
Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Duggan L, et al. Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD001359. doi: 10.1002/14651858.CD001359.pub2. Cochrane Database Syst Rev. 2005. PMID: 15846619 Free PMC article.
Although dizziness and dry mouth were reported more frequently in the olanzapine-treated group, this did not reach statistical significance. The olanzapine group gained more weight. ...For people with treatment-resistant illness there were no clear differences betwe …
Although dizziness and dry mouth were reported more frequently in the olanzapine-treated group, this did not reach statistical signif …
Olanzapine in oncology palliative care.
Šoukalová Z. Šoukalová Z. Klin Onkol. 2022 Summer;35(4):276-283. doi: 10.48095/ccko2022276. Klin Onkol. 2022. PMID: 35989084 Review. English.
BACKGROUND: Olanzapine is an effective antipsychotic drug used in psychiatry to treat psychoses, especially schizophrenia and schizoaffective disorders. ...Olanzapine is an effective treatment for delirium, as effective as haloperidol, but with a lower toxicity prof …
BACKGROUND: Olanzapine is an effective antipsychotic drug used in psychiatry to treat psychoses, especially schizophrenia and schizoa …
Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Soares-Weiser K, Béchard-Evans L, Lawson AH, Davis J, Ascher-Svanum H. Soares-Weiser K, et al. Eur Neuropsychopharmacol. 2013 Feb;23(2):118-25. doi: 10.1016/j.euroneuro.2012.05.001. Epub 2012 May 26. Eur Neuropsychopharmacol. 2013. PMID: 22633617
There were no significant differences between olanzapine and clozapine in RCTs or observational studies. All-cause discontinuation rates in RCTs were significantly lower for olanzapine compared to all comparators except amisulpride and clozapine. In observational st …
There were no significant differences between olanzapine and clozapine in RCTs or observational studies. All-cause discontinuation ra …
The Benefits of Olanzapine in Palliating Symptoms.
Davis MP, Sanger GJ. Davis MP, et al. Curr Treat Options Oncol. 2020 Nov 26;22(1):5. doi: 10.1007/s11864-020-00804-1. Curr Treat Options Oncol. 2020. PMID: 33244634 Review.
Olanzapine has become a major drug in the management of chemotherapy-induced nausea and vomiting as a prophylactic agent. ...The benefits of adding olanzapine to potent opioids are that it may reduce craving, drug cues, and opioid misuse. ...
Olanzapine has become a major drug in the management of chemotherapy-induced nausea and vomiting as a prophylactic agent. ...The bene …
Impaired mitophagosome-lysosome fusion mediates olanzapine-induced aging.
Chen X, Wang Z, Zheng P, Dongol A, Xie Y, Ge X, Zheng M, Dang X, Seyhan ZB, Nagaratnam N, Yu Y, Huang XF. Chen X, et al. Aging Cell. 2023 Nov;22(11):e14003. doi: 10.1111/acel.14003. Epub 2023 Oct 13. Aging Cell. 2023. PMID: 37828862 Free PMC article.
Here we report that dysfunctional mitophagy is a fundamental mechanism underlying accelerated aging induced by olanzapine, using in vitro and in vivo (Caenorhabditis elegans) models. We showed that the aberrant mitophagy caused by olanzapine was via blocking mitopha …
Here we report that dysfunctional mitophagy is a fundamental mechanism underlying accelerated aging induced by olanzapine, using in v …
11,912 results
You have reached the last available page of results. Please see the User Guide for more information.